Lilly’s $3.8B AtaiBeckley deal brings psychedelics into big pharma
The acquisition gives Eli Lilly a late-stage psychedelic treatment for resistant depression, with $2.8B upfront and up to $1B in milestones.
Eli Lilly’s agreement to acquire AtaiBeckley for up to $3.8B moves psychedelic medicine further from a speculative biotech niche into mainstream pharmaceutical development.
What happened
Lilly agreed to pay $2.8B upfront for AtaiBeckley, with up to another $1B tied to development and regulatory milestones.
The transaction gives Lilly access to BPL-003, a nasal-spray treatment based on a psychedelic compound and being developed for treatment-resistant depression. Initial late-stage trial results are expected in 2029.
The acquisition price therefore reflects both the potential of the asset and the substantial clinical work still required before commercialisation.
Why it matters
Treatment-resistant depression affects patients who do not respond adequately to existing medicines. Psychedelic-derived therapies may offer a new mechanism and potentially faster effects, but they face challenges around dosing, supervision, durability and patient selection.
A company of Lilly’s scale can fund large trials, regulatory work and commercial infrastructure that smaller psychedelic developers may struggle to support independently.
The bigger picture
The deal is a validation of the category, not proof that the treatment will succeed. BPL-003 must still perform in large controlled studies and satisfy regulators on safety, effectiveness and how treatment is administered.
If approved, the commercial model may differ from ordinary prescription drugs because psychedelic treatments can require monitored clinical sessions. Lilly will need to show that the therapy can be delivered consistently and economically across real healthcare systems.